The Pharma Data

NOVEMBER 4, 2020

Ltd (“Juyou”), a biotechnology company that develops and sells medical and cosmetic skincare products, for the commercialization and development of Pliaglis ® in mainland China (the “License Agreement”). million and US$1.8 For additional information, please visit [link].

Licensing 40

Licensing Licensing Production Engineering 40

Codon

SEPTEMBER 29, 2024

At best, the corporations with the best models released weak versions to the public under non-commercial licenses. Most crops were now genetically-engineered to tolerate flood, drought, pests, and disease. While this had been the norm long before the first models of life, the extent of engineering went far beyond the last generation.

Engineering 142

Engineering Virus DNA Therapies 142

Molecule Blog

MARCH 17, 2023

The university then licenses the IP to an existing pharmaceutical company or a biotech startup, which takes on Investigational New Drug (IND) enabling studies. In this regard, BioDAOs can be viewed as collaborative research translation engines and a novel form of biotech organization that develops IP through an online-native approach.

Engineering 52

Engineering Research Clinical Trials Government 52

Codon

JUNE 30, 2024

Stanley Cohen and Herb Boyer—professors at Stanford and UC San Francisco, respectively— met the following year in a Hawaiian delicatessen to discuss how the new method, called recombinant DNA technology, could be employed to engineer living cells to make useful products. The race to exploit recombinant DNA technology was on.

DNA 105

DNA Engineering Laboratories Production 105

Codon

FEBRUARY 13, 2024

Phage-based products have been licensed for use as antibacterial agents in the sanitation , food production , and animal health industries. Crucially, it could also make them easier to license as therapeutic agents. The resulting data are fed into an analytical engine that runs millions of simulations. aeruginosa, S. pneumoniae.

Therapies 131

Therapies Virus DNA Clinical Trials 131

Drug Target Review

SEPTEMBER 7, 2023

The second part of this therapy engineers the donor’s T cells so that they no longer express their native T cell receptor, but now express a T cell receptor reactive against the haematopoietically-restricted minor histocompatibility antigen HA-1. However, the T cells are also what drive the graft-versus leukaemia effect.

Treatment 98

Treatment Licensing Licensing Disease 98

Drug Target Review

APRIL 5, 2024

For example, a CDMO with deep sequencing knowledge and a proprietary cell line will achieve significantly better performance than CDMOs that license third-party technologies.

Protein Production 96

Protein Production Protein Expression Bioinformatics Production 96

Perficient: Drug Development

AUGUST 1, 2023

Content Management Systems and Templating In the past, I have worked with various Content Management Systems, including Drupal, which utilized the Twig templating engine to generate the HTML for web pages. The App was built on top of the “HTL Engine for JavaScript” library written by Adobe. Everything went quite smoothly.

Engineering 52

Engineering Packaging Licensing Licensing 52

Drug Target Review

FEBRUARY 28, 2024

These include engineering the cells to express cytokines that promote their maturation and/or differentiation, and engineering drug-resistant γδ T cells that can be combined with chemotherapies, which stress cancer cells but would otherwise also deplete the T-cell population. Kabelitz D, Serrano R, Kouakanou L, et al.

Therapies 105

Therapies Engineering Molecular Biology Science 105

The Pharma Data

DECEMBER 17, 2020

Merck will select cancer targets and harness Janux’s proprietary Tumor Activated T Cell Engager (TRACTr) technology to engineer novel, T cell engager drug candidates. Under the terms of the agreement, Merck received an exclusive worldwide license to products and intellectual property developed from this collaboration.

Immune Response 52

Immune Response Pharmacokinetics Engineering Licensing 52

Codon

APRIL 2, 2023

This is Codon Digest, a weekly roundup of research papers, news articles, and industry highlights about engineered biology. Read Biological Engineering mScarlet3: a brilliant and fast-maturing red fluorescent protein. CRISPRi-mediated tunable control of gene expression level with engineered single-guide RNA in Escherichia coli.

DNA 52

DNA RNA Engineering Licensing 52

The Pharma Data

JANUARY 17, 2021

Based in Seattle, Washington, Sana focuses on in vivo and ex vivo cell engineering platforms to develop therapies for cancer, diabetes, cardiovascular disease, CNS disorders, and genetic diseases. But that number doesn’t quite reflect the company’s likely market valuation , which is expected to be between $9 billion and $12 billion.

Marketing 52

Marketing Engineering Therapies Disease 52

The Pharma Data

APRIL 12, 2023

Nasdaq: DNLI) today announced that Biogen has exercised the option to license Denali’s Antibody Transport Vehicle (ATV): Amyloid beta program (ATV:Aβ). We are pleased with Biogen’s decision to license ATV: Aβ and we are hopeful this will foster the development of next-generation anti- Aβ therapeutics.”

Engineering 40

Engineering Licensing Licensing Treatment 40

Translation

MARCH 1, 2024

Brent Fagg currently serves as Virginia Commonwealth University’s Senior Licensing Manager in their TechTransfer and Ventures unit. For instance, when engaging a private engineering firm, costs might be presented as $150/hour for a junior engineer. This ongoing dialogue provided a new opportunity for our partnership.

Licensing 40

Licensing Licensing Engineering Research 40

The Pharma Data

JANUARY 25, 2021

Ambulero holds an exclusive license from the University of Miami to develop and commercialize research from the laboratories of Drs. Ambulero’s cell therapy program uses stromal cells engineered to express E-selectin to promote tissue repair. As part of the investment, Ambulero and Orphinic formed a Polish subsidiary (Ambulero Sp.

Therapies 52

Therapies Disease Licensing Licensing 52

DrugBaron

NOVEMBER 9, 2020

Indeed, China has already licensed a vaccine, albeit without the data that would typically be required to support such an approval. The real engine beyind light-speed progress towards a COBID vaccine has been strategic focus. And despite that, progress, while real in some limited areas, has been modest.

Vaccine 100

Vaccine Pharmaceutical Companies Government Pharmaceuticals 100

Codon

JULY 14, 2024

5 An added benefit of PSCs is that they are amenable to genetic modifications, making it possible to engineer blood cells with specific properties. Cultured red blood cells can also be genetically engineered to act as synthetic sensors that detect circulating molecules inside the body.

Production 141

Production Clinical Trials Trials Therapies 141

Perficient: Drug Development

FEBRUARY 13, 2024

Elasticsearch, functioning as a local search engine, indexes the data into ‘Apache Lucene’ files and retrieves search results based on indexed data, significantly speeding up search operations compared to database queries.

Licensing 52

Licensing Licensing Engineering Production 52

The Pharma Data

MARCH 29, 2022

Engineered IgM antibodies represent a new class of potential therapeutics that combine the multi-valency of IgM antibodies possessing 10 binding sites compared to conventional IgG antibodies having only 2 target binding sites. Sanofi has also expressed an interest in purchasing up to $100M of IGM non-voting common stock in a public financing.

Clinical Trials 52

Clinical Trials Engineering Licensing Licensing 52

The Pharma Data

SEPTEMBER 30, 2021

Anderson Professor of Chemical and Biomolecular Engineering, and his colleagues, are reporting in iScience the event of an intranasal subunit vaccine that gives durable local immunity against inhaled pathogens. But now, we’re one step closer. Navin Varadarajan, University of Houston M.D.

Vaccine 52

Vaccine Disease Immune Response Virus 52

The Pharma Data

DECEMBER 13, 2020

MacroGenics , based in Rockville, Maryland, has a target action date of December 18 for its Biologics License Application (BLA) for margetuximab in combination with chemotherapy for patients with metastatic HER2+ breast cancer. Margetuximab is an investigational, Fc-engineered, monoclonal antibody targeting HER2.

FDA 52

FDA Biosimilars Clinical Trials Licensing 52

The Pharma Data

DECEMBER 9, 2020

Under its ongoing collaboration and license agreement, Crescendo’s proprietary transgenic platform and engineering expertise is being used to build Humabody ® -based therapeutics against certain targets selected by Takeda. This is the sixth technical milestone achieved by Crescendo in its collaboration with Takeda.

Licensing 40

Licensing Licensing Pharmaceutical Companies Engineering 40

The Pharma Data

NOVEMBER 8, 2020

The Series B financing will be mainly used to conduct global clinical trials, research and development, and product in-licensing activities. To date, Inmagene has raised over $40 million financing. Inmagene is a leading drug development company focused on immunology-related therapeutic areas.

Clinical Trials 40

Clinical Trials Licensing Licensing Drug Development 40

Advarra

AUGUST 10, 2023

This will aid clinical development and preparation for investigational new drug (IND) and biologics license application (BLA) submissions. How Can Research Professionals Mitigate Risks with Engineered Genetic Materials? Gene therapy products may pose unknown risks, and Dr. Marks said there is much to learn about the field. “We

Drug Development 52

Drug Development Disease Therapies Engineering 52

The Pharma Data

JANUARY 12, 2021

With the phase of the Agreement relating to the development of the antibody completed, under the Agreement, as of 11 January 2021, GlobalCo has three months to exercise an option to license the Company’s intellectual property necessary to exploit the CDX antibody on an exclusive worldwide basis (“Option”).

Pharmaceuticals 40

Pharmaceuticals Licensing Licensing Clinical Trials 40

The Pharma Data

MARCH 9, 2021

. (“Biolojic”), a biotechnology company that computationally designs functional antibodies, today announced a research collaboration and license agreement that will leverage Biolojic’s AI-based multibody platform to discover and develop a potential novel antibody-based therapy for the treatment of diabetes.

Therapies 52

Therapies Research Licensing Licensing 52

The Pharma Data

JANUARY 4, 2021

05, 2021 (GLOBE NEWSWIRE) — ViGeneron GmbH , a gene therapy company, today announced a global collaboration and licensing agreement with Biogen Inc. The companies will use ViGeneron’s proprietary vgAAV, novel engineered AAV capsids, to efficiently transduce retinal cells via intravitreal injections. . MUNICH, Germany, Jan.

Therapies 52

Therapies Virus Disease Licensing 52

FDA Law Blog: Drug Discovery

JANUARY 4, 2023

Brevig, Senior Regulatory Device and Biologics Expert — On December 7, 2022, FDA’s Center for Biologics Evaluation and Research (CBER) and the Office of Tissues and Advanced Therapies (OTAT) held a town hall to answer questions related to cell therapy and tissue-engineered products chemistry, manufacturing, and contr­­ols (CMC).

Therapies 59

Therapies Engineering Production FDA 59

Perficient: Drug Development

JUNE 7, 2023

Magento offers powerful marketing, search engine optimization, and Catalog management tools. Magento is a largely customizable E-Commerce platform available under both open-source and marketable licenses. It’s open-source software, which is handy for online business. Magento 2 is presently the largest e-commerce.

Licensing 52

Licensing Licensing Engineering Marketing 52

The Pharma Data

MAY 4, 2021

Gilead sues Russia over a compulsory license issued to a company making remdesivir ( STAT ). Lilly accelerating baricitinib’s availability in India following receipt of permission for restricted emergency use as a COVID-19 therapy via donations and licensing agreements ( Press ). Interim Order No.

Vaccine 52

Vaccine FDA Approval FDA Licensing 52

Broad Institute

JULY 25, 2024

Researchers identify cheap and effective biomarkers for DCIS tumor stage By Tom Ulrich July 25, 2024 Breadcrumb Home Researchers identify cheap and effective biomarkers for DCIS tumor stage New study shows how leveraging unsupervised learning can decode DCIS progression from chromatin images.

Research 69

Research Disease Treatment Clinical Trials 69

Drug Target Review

JULY 6, 2023

3 Furthermore, the act “removes a requirement to use animal studies as part of the process to obtain a license for a biological product that is biosimilar or interchangeable with another biological product.” Overall, there are several alternatives to animal testing that can be used in pre-clinical research.

Animal Testing 105

Animal Testing Drugs Clinical Trials Clinical Research 105

Perficient: Drug Development

OCTOBER 31, 2023

Requirements: Active Katalon Runtime Engine license. CI/CD Integration Autonomous testing interfaces with CI/CD methods to effortlessly fit into contemporary software development pipelines. Continuous testing and quick feedback are ensured by tests automatically triggered by code commits.

Licensing 52

Licensing Licensing Engineering Production 52

The Pharma Data

JANUARY 17, 2021

Taconic Biosciences is a fully-licensed, global leader in genetically engineered rodent models and services. Founded in 1952, Taconic provides the best animal solutions so that customers can acquire, custom-generate, breed, precondition, test, and distribute valuable research models worldwide.

Immune Response 40

Immune Response Pharmacokinetics Engineering Licensing 40

The Pharma Data

NOVEMBER 18, 2020

SEFA’ stands for Structurally Engineered Fatty Acid, i.e. chemically engineered fatty acids, to generate compounds with differentiated physiochemical properties. This Phase 1 trial will evaluate the safety, tolerability, and pharmacokinetics of SEFA-1024 in 96 otherwise healthy volunteers with elevated plasma triglyceride levels.

Trials 40

Trials Engineering Pharmacokinetics Therapies 40

The Pharma Data

NOVEMBER 22, 2020

The company has an exclusive collaboration and license deal with CStone Pharmaceuticals for development and commercialization of pralsetinib and specific other drug candidates in Mainland China, Hong Kong, Macau and Taiwan. It holds the rights for the drug in the rest of the world. Revance Therapeutics’ DAXI to Treat Frown Lines.

FDA 52

FDA Licensing Licensing Treatment 52

Perficient: Drug Development

FEBRUARY 14, 2024

Whether you license content from a health library or write your own, people already know where to go and whom to trust for the educational content. And it becomes a conversion engine and a net driver of revenue. Healthcare writing training teaches you how to write for healthcare SEO True search-engine optimization (SEO) is important.

Engineering 52

Engineering International Marketing Licensing 52